Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inflammatory Markers and Adipokines Related to Cardiovascular Risk and Metabolic Comorbidities in Psoriatic Arthritis treated with Apremilast

Trial Profile

Inflammatory Markers and Adipokines Related to Cardiovascular Risk and Metabolic Comorbidities in Psoriatic Arthritis treated with Apremilast

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Apremilast (Primary)
  • Indications Psoriatic arthritis
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 17 Jul 2018 New trial record
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top